Phosphodiesterase 4 inhibitors as novel
β
Annette M Doherty
π
Article
π
1999
π
Elsevier Science
π
English
β 957 KB
and clinical studies of phosphodiesterase 4 inhibitors have shown that these agents may find utility in a wide range of inflammatory disorders, including asthma, chronic obstructive pulmonary disease, atopic dermatitis, rheumatoid arthritis, multiple sclerosis and various neurological disorders. The